Temple University. Philadelphia, PA, USA.
Johns Hopkins University, Baltimore, MD, USA.
Neurogastroenterol Motil. 2021 Aug;33(8):e14087. doi: 10.1111/nmo.14087. Epub 2021 Jan 25.
BACKGROUND: Understanding factors that impair quality of life (QOL) in gastroparesis is important for clinical management. AIMS: (a) Determine QOL in patients with gastroparesis; (b) Determine factors that impair QOL. METHODS: Gastroparetic patientsAQ6 underwent history and questionnaires assessing symptoms (PAGI-SYM and Rome III), QOL (SF-36v2 and PAGI-QOL), depression (Beck Depression Inventory [BDI]), and anxiety (State Trait Anxiety InventoryAQ7). KEY RESULTS: 715 gastroparesis patients (256 diabetic (DG), 459 idiopathic (IG)) were evaluated. SF-36 physical component (PC) score averaged 33.3 ± 10.5; 41% had impaired score <30. SF-36 PC scores were similar between diabetic and idiopathic gastroparesis. Impaired SF-36 PC associated with increased nausea/vomiting and upper abdominal pain subscores, acute onset of symptoms, higher number of comorbidities, use of narcotic pain medications, and irritable bowel syndrome (IBS). SF-36 mental component (MC) score averaged 38.9 ± 13.0; 26% had impaired score <30. Poor SF-36 MC associated with diabetic etiology, higher Beck depression inventory, and state anxiety scores. PAGI-QOL score averaged 2.6 ± 1.1; 50% had a score of <2.6. Low PAGI-QOL associated with higher fullness, bloating, and upper abdominal pain subscores, more depression and Trait anxiety, smoking cigarettes, need for nutritional support, progressively worsening symptoms and periodic exacerbations. CONCLUSIONS & INFERENCES: Multiple measures show poor QOL present in gastroparesis. Several areas impacted on reduced QOL: (a) Symptoms of nausea, vomiting, and abdominal pain, as well as IBS; (b) Etiology and acute onset and progressively worsening symptoms; (c) Comorbidities and psychological factors such as anxiety and depression; (d) Patient-related factors such as smoking. Targeting the modifiable factors may improve patient outcomes in gastroparesis.
背景:了解影响胃轻瘫患者生活质量(QOL)的因素对于临床管理很重要。
目的:(a)确定胃轻瘫患者的 QOL;(b)确定影响 QOL 的因素。
方法:胃轻瘫患者接受了病史和问卷评估,包括症状(PAGI-SYM 和 Rome III)、QOL(SF-36v2 和 PAGI-QOL)、抑郁(贝克抑郁量表[BDI])和焦虑(状态特质焦虑量表 AQ7)。
主要结果:共评估了 715 例胃轻瘫患者(256 例糖尿病性[DG],459 例特发性[IG])。SF-36 生理成分(PC)评分平均为 33.3±10.5;41%的患者得分<30,表明 PC 评分受损。糖尿病性和特发性胃轻瘫患者的 SF-36 PC 评分相似。PC 评分受损与恶心/呕吐和上腹痛亚量表评分增加、症状急性发作、合并症数量增加、使用麻醉性止痛药和肠易激综合征(IBS)相关。SF-36 心理成分(MC)评分平均为 38.9±13.0;26%的患者得分<30,表明 MC 评分受损。SF-36 MC 评分差与糖尿病病因、更高的贝克抑郁量表和状态焦虑评分相关。PAGI-QOL 评分平均为 2.6±1.1;50%的患者评分<2.6,表明 QOL 较低。PAGI-QOL 评分低与饱胀感、腹胀和上腹痛亚量表评分增加、更多的抑郁和特质焦虑、吸烟、需要营养支持、症状逐渐恶化和周期性加重相关。
结论:多项指标表明胃轻瘫患者的 QOL 较差。多个方面影响 QOL 降低:(a)恶心、呕吐和腹痛以及 IBS 等症状;(b)病因、急性发作和逐渐恶化的症状;(c)合并症和焦虑、抑郁等心理因素;(d)患者相关因素,如吸烟。针对可改变的因素可能会改善胃轻瘫患者的预后。
Neurogastroenterol Motil. 2021-8
Neurogastroenterol Motil. 2013-2-17
Neurogastroenterol Motil. 2016-12
Neurogastroenterol Motil. 2011-11-27
Neurogastroenterol Motil. 2020-2
Clin Gastroenterol Hepatol. 2018-11-4
J Clin Med. 2024-11-25
Front Med (Lausanne). 2024-10-10
Transl Gastroenterol Hepatol. 2024-7-10
JPEN J Parenter Enteral Nutr. 2023-5
Clin Gastroenterol Hepatol. 2022-12
Dig Dis Sci. 2017-4
Neurogastroenterol Motil. 2016-12
Gastroenterology. 2015-8-21
Neurogastroenterol Motil. 2013-2-17
Aliment Pharmacol Ther. 2012-11-5
Neurogastroenterol Motil. 2011-11-27
Clin Gastroenterol Hepatol. 2011-8-24
Am J Gastroenterol. 2011-4-12
J Clin Gastroenterol. 2011-4